Clinical Trials

Triple Negative Breast Neoplasms

NCT06132958 2026-04-03

TroFuse-005

710 enrolled

Gynecologic

Endometrial Neoplasms

NCT06312176 2026-04-02

MK-2870-010

Phase 3 Recruiting

1,200 enrolled

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04104672 2026-03-31

ARC-8

196 enrolled

Pancreatic Neoplasms

NCT07076121 2026-03-31

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Phase 2/3 Recruiting

470 enrolled

Pancreatic Neoplasms

NCT05586516 2026-03-30

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

16 enrolled

Phase 1 Active not recruiting

Fibrosis, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05017012 2026-03-27

MK-3475A-C18

72 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT06953323 2026-03-27

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

86 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05771480 2026-03-25

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT04894643 2026-03-20

PARC

Phase NA Recruiting

10 enrolled

Phase 2 Not yet recruiting

Pancreatic Neoplasms

NCT07483554 2026-03-19

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

389 enrolled

CLDN18.2 Positive

NCT04165070 2026-03-16

MK-3475-01A

450 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 2 FDA

Phase 1 Active not recruiting

Non Small Cell Lung Cancer NSCLC

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT04083235 2026-03-09

NAPOLI 3

770 enrolled 13 charts 2 FDA

Metastatic Adenocarcinoma of the Pancreas

NCT06953999 2026-03-04

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

Phase 3 Recruiting

999 enrolled

Pancreatic Neoplasms

NCT03976362 2026-02-25

KEYLYNK-008

851 enrolled 25 charts

Tumor-Agnostic

Carcinoma

NCT06447662 2026-02-25

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

330 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT02705196 2026-02-24

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Phase 1/2 Completed

51 enrolled

Adenoviridae Infections, Neoplasms, Pancreatic Neoplasms

NCT06731907 2026-02-18

MK-3475-01G

Phase 2 Recruiting

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

220 enrolled

Triple Negative Breast Neoplasms

NCT05226598 2026-02-05

MK-7684A-007

739 enrolled 12 charts

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT07383922 2026-02-04

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

Phase 3 Not yet recruiting

524 enrolled

Pancreatic Neoplasms

NCT03456063 2026-01-22

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

453 enrolled

Non-Small-Cell Lung

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

184 enrolled 15 charts

Phase 1/2 Active not recruiting

Triple Negative Breast Neoplasms

NCT04396821 2025-12-17

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

150 enrolled

Pancreatic Neoplasms, Stomach Neoplasms

NCT07280377 2025-12-12

GOBLET

122 enrolled

Anal Cancer Metastatic

NCT03257033 2025-11-14

TIGeR-PaC

Phase 3 Recruiting

190 enrolled

Locally Advanced Pancreatic Cancer

NCT06212752 2025-11-12

MK-3475A-D77

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03396445 2025-11-05

MK-5890-001

Phase 1 Completed

182 enrolled 36 charts

BreastThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

258 enrolled

Biliary Tract Neoplasms

NCT03776812 2025-10-07

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

178 enrolled 21 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05840211 2025-10-03

ASCENT-07

654 enrolled

Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

443 enrolled

Triple Negative Breast Neoplasms

NCT05722015 2025-09-11

MK-3475A-D77

377 enrolled 17 charts 3 FDA

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05669482 2025-09-02

RAMP205

40 enrolled